Payment overview · 2025
General Payments
$6,531.30
50 reported records · 16 companies
Healthcare provider profile · identity verified
Melissa A Gaines, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1376557264
Verified facts
What the public records show
CMS Open Payments records show Melissa A Gaines, MD received $6,531.30 in general payments during 2025 across 50 reported records.
Lilly USA, LLC accounted for 85.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Entresto, Farxiga, Ozempic, Paxlovid, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $5,573.00 | 85.3% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $333.23 | 5.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $191.33 | 2.9% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.91 | 1.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.82 | 1.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.88 | 0.7% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $37.03 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.51 | 0.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.80 | 0.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.75 | 0.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.87 | 0.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.38 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.49 | 0.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.45 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.60 | 0.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,400.00 | 3 |
| Food and Beverage | $1,131.30 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $5,554.59 | 8 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $333.23 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.46 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $94.91 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.88 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $90.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.72 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.82 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.88 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $37.03 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 75 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 410 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 34 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
410 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
75 | 75 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
410 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 994 | 229 |
| Atorvastatin Calcium | Atorvastatin Calcium | 831 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 613 | 155 |
| Lisinopril | Lisinopril | 572 | 145 |
| Omeprazole | Omeprazole | 557 | 135 |
| Gabapentin | Gabapentin | 544 | 115 |
| Losartan Potassium | Losartan Potassium | 542 | 134 |
| Duloxetine Hcl | Duloxetine Hcl | 473 | 91 |
| Potassium Chloride | Potassium Chloride | 444 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 119 |
| Trazodone Hcl | Trazodone Hcl | 423 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 418 | 142 |
| Pravastatin Sodium | Pravastatin Sodium | 415 | 105 |
| Eliquis | Apixaban | 410 | 72 |
| Spironolactone | Spironolactone | 383 | 84 |
| Tramadol Hcl | Tramadol Hcl | 311 | 105 |
| Carvedilol | Carvedilol | 307 | 69 |
| Meloxicam | Meloxicam | 298 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 80 |
| Simvastatin | Simvastatin | 263 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 61 |
| Oxycodone Hcl | Oxycodone Hcl | 232 | 59 |
| Lorazepam | Lorazepam | 225 | 62 |
| Irbesartan | Irbesartan | 219 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 59 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 218 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 56 |
| Pregabalin | Pregabalin | 211 | 55 |
| Famotidine | Famotidine | 196 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 66 |
| Metformin Hcl Er | Metformin Hcl | 188 | 46 |
| Allopurinol | Allopurinol | 187 | 46 |
| Sertraline Hcl | Sertraline Hcl | 187 | 43 |
| Mirtazapine | Mirtazapine | 179 | 41 |
| Bupropion Xl | Bupropion Hcl | 176 | 53 |
| Torsemide | Torsemide | 176 | 34 |
| Furosemide | Furosemide | 171 | 52 |
| Metformin Hcl | Metformin Hcl | 171 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 59 |
| Alprazolam | Alprazolam | 162 | 53 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 158 | 43 |
| Montelukast Sodium | Montelukast Sodium | 158 | 34 |
| Buspirone Hcl | Buspirone Hcl | 156 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 38 |
| Baclofen | Baclofen | 136 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 129 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 128 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Jardiance | Empagliflozin | 102 | 17 |
| Prednisone | Prednisone | 101 | 46 |
| Alendronate Sodium | Alendronate Sodium | 95 | 23 |
| Farxiga | Dapagliflozin Propanediol | 95 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 28 |
| Memantine Hcl | Memantine Hcl | 93 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 93 | 21 |
| Xarelto | Rivaroxaban | 92 | 17 |
| Calcitriol | Calcitriol | 85 | suppressed |
| Clonazepam | Clonazepam | 85 | 26 |
| Ezetimibe | Ezetimibe | 85 | 22 |
| Warfarin Sodium | Warfarin Sodium | 84 | 17 |
| Celecoxib | Celecoxib | 83 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Chlorthalidone | Chlorthalidone | 76 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 75 | 75 |
| Synthroid | Levothyroxine Sodium | 71 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 33 |
| Divalproex Sodium | Divalproex Sodium | 67 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 13 |
| Amoxicillin | Amoxicillin | 64 | 38 |
| Lovastatin | Lovastatin | 64 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 13 |
| Diflunisal | Diflunisal | 63 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 18 |
| Donepezil Hcl | Donepezil Hcl | 60 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 43 |
| Buprenorphine | Buprenorphine | 58 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | suppressed |
| Klor-Con M20 | Potassium Chloride | 56 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 56 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 55 | 37 |
| Ozempic | Semaglutide | 55 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 28 |
| Myrbetriq | Mirabegron | 54 | 14 |
| Atenolol | Atenolol | 53 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 11 |
| Bumetanide | Bumetanide | 49 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Finasteride | Finasteride | 46 | 15 |
| Cephalexin | Cephalexin | 44 | 32 |
| Midodrine Hcl | Midodrine Hcl | 44 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 12 |
| Acyclovir | Acyclovir | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 31 |
| Tdvax | Tetanus, Diphtheria Tox,adult | 38 | 38 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Estradiol | Estradiol | 36 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 11 |
| Fluconazole | Fluconazole | 35 | 20 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 13 |
| Fentanyl | Fentanyl | 33 | 12 |
| Temazepam | Temazepam | 33 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 13 |
| Lactulose | Lactulose | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Topiramate | Topiramate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 16 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Glipizide | Glipizide | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 21 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 15 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Cartia Xt | Diltiazem Hcl | 20 | 12 |
| Tramadol Hcl Er | Tramadol Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,531.30 · 50 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AMYVID, BREZTRI, Belbuca, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE, KISUNLA, Kerendia, LEQVIO, Leqembi, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, Senza, XIFAXAN, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error